|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2005-10-19
|
|
pubmed:abstractText |
The synthesis and biological evaluation of novel 3-amino indazole melanin concentrating hormone receptor-1 antagonists are reported, several of which demonstrated functional activity of less than 100nM. Compounds 19 and 28, two of the more potent compounds identified in this study, were characterized by high exposure in the brain and demonstrated robust efficacy when dosed in diet-induced obese mice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BrodjianSevanS,
pubmed-author:BruneMichaelM,
pubmed-author:BushEugeneE,
pubmed-author:CollinsChristine ACA,
pubmed-author:DaytonBrianB,
pubmed-author:EngstromKenneth MKM,
pubmed-author:FallsDoug HDH,
pubmed-author:FreemanJennifer CJC,
pubmed-author:HernandezLisa ELE,
pubmed-author:JOBCC,
pubmed-author:KymPhilip RPR,
pubmed-author:LynchJohn KJK,
pubmed-author:MarshKennan CKC,
pubmed-author:MulhernMathew MMM,
pubmed-author:ShapiroRobin DRD,
pubmed-author:SouersAndrew JAJ,
pubmed-author:VasudevanAnilA,
pubmed-author:VerzalMary KMK,
pubmed-author:WagawSeble HSH,
pubmed-author:WodkaDerekD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5293-7
|
|
pubmed:dateRevised |
2006-6-1
|
|
pubmed:meshHeading |
pubmed-meshheading:16203136-Administration, Oral,
pubmed-meshheading:16203136-Animals,
pubmed-meshheading:16203136-Anti-Obesity Agents,
pubmed-meshheading:16203136-Humans,
pubmed-meshheading:16203136-Indazoles,
pubmed-meshheading:16203136-Mice,
pubmed-meshheading:16203136-Piperidines,
pubmed-meshheading:16203136-Receptors, Somatostatin,
pubmed-meshheading:16203136-Tissue Distribution
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.
|
|
pubmed:affiliation |
Metabolic Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. Anil.Vasudevan@abbott.com
|
|
pubmed:publicationType |
Journal Article
|
